09/11/2021 (Agence Europe) – The European Medicines Agency (EMA) announced on Monday 8 November that it would provide additional guidance to Member States' health authorities on the oral antiviral drug molnupiravir (see EUROPE B12819A21), with a view to authorising the use of this possible Covid-19 treatment for emergency situations. Molnupiravir, developed by Merck, was approved last week in the UK, but is still awaiting market authorisation in Europe. The EMA is continuing to work on...